Politics By Nicholas Florko Trump claims his policies made insulin ‘so cheap, it’s like water.’ But for most people, it costs just as much as before
First Opinion By Nathan Yates I have spinal muscular atrophy. Critics of the $2 million new gene therapy are missing the point
First Opinion By William S. Smith The Biden administration needs to look beyond ICER for evaluating drug therapies
Pharmalot By Ed Silverman The CEO of Mark Cuban’s generics company talks drug prices, manufacturing, and his famous boss
Pharmalot By Ed Silverman Pharmacy benefit managers take heavy criticism from a new source: local officials
Politics By Lev Facher States still can’t import drugs from Canada. Now, many are seeking to import Canadian prices
Pharmalot By Ed Silverman Once again, senators want GAO to probe the role of PBMs in prescription drug pricing
Pharmalot By Ed Silverman With a legislative vote, Maryland’s prescription drug affordability board moves forward
Pharmalot By Ed Silverman Drug maker will slash prices on cancer medicines to end price gouging probe in Europe
Pharmalot By Ed Silverman Pharmalittle: House Dems slip drug pricing proposal into Covid-19 relief bill; FDA grants emergency use for Lilly drug
Pharmalot By Ed Silverman U.S. drug prices were more than double those in dozens of countries in 2018
Pharmalot By Ed Silverman Pharma is only ‘inching forward’ in boosting access to medicines in low-income countries
Pharmalot By Ed Silverman This academic published a manual for using a little-known federal law for lowering drug prices
Pharmalot By Ed Silverman Canada’s drug makers rattle their sabers over a government plan to control medicine spending
Pharmalot By Ed Silverman Will the FTC get tougher on pharma business practices under the Biden administration?
Pharmalot By Ed Silverman Maryland Senate overrides governor’s veto of prescription drug affordability board
Pharmalot By Ed Silverman The prices of 7 drugs were hiked without proof of new benefits, costing the U.S. $1.2 billion in 2019
Pharmalot By Ed Silverman Commerce Department agency proposes eliminating ‘march-in rights’ as a tool to lower drug prices
Biotech By Matthew Herper Company dedicated to cutting drug prices raises lots of money, releases few details
Politics By Nicholas Florko and Lev Facher Democrats have their best shot yet at letting Medicare negotiate drug prices — but it’s still not a done deal
Pharmalot By Ed Silverman Tennessee to become the first state to run a closed Medicaid drug formulary
Pharmalot By Ed Silverman Generic drug makers fear a ‘skinny labeling’ court ruling will pose a huge threat